RecruitingNCT06183658

Greater-Bay-Area Healthy Aging Brain Study (GHABS)

Greater-Bay-Area Healthy Aging Brain Study (GHABS): Biomarker- and Neuroimaging-based Study of the Pathophysiology Characterization and Evolutionary Patterns of Alzheimer's Disease

Sponsor

Shenzhen Bay Laboratory

Enrollment

1,400 participants

Start Date

May 1, 2021

Study Type

OBSERVATIONAL

Conditions

Alzheimer s Disease

Summary

The goal of this observational study is to learn about the pathophysiology characterization and evolutionary patterns of Alzheimer's disease (AD) in South China older adults. The primary purposes are as follows: 1. The prevalence and characteristics of AD in South China's aging population 2. Identify novel biomarkers and neuroimaging techniques for early detection and intervention of AD 3. Supporting and fertilizing novel approaches and techniques for early diagnosis and intervention of AD Participants will undergo cognitive assessments, blood sample collection, and genetic testing. Some will undergo CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning.

Eligibility

Min Age: 55 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study — the Greater-Bay-Area Healthy Aging Brain Study (GHABS) — follows older adults in the Greater Bay Area of China to understand the factors that affect brain aging, memory, and risk of Alzheimer's disease. It tracks participants over time with cognitive tests, brain scans, and blood tests to identify early markers of cognitive decline. **You may be eligible if...** - You are between 55 and 90 years old (or younger if you have a family history of early-onset Alzheimer's) - You score below 6 on the Geriatric Depression Scale (low depression burden) - You have a caregiver or family member who can participate alongside you - You are willing to undergo imaging and cognitive testing **You may NOT be eligible if...** - You have a severe physical or mental illness that prevents participation - You are unable to give informed consent or complete the study assessments - You have moderate to severe depression - You are unable to access the study center Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFluids biomarker and neuroimaging of AD diagnosis

Early diagnosis of Alzheimer's disease in South China aging population using fluids biomarker and neuroimaging.

Locations(1)

Shenzhen Bay Laboratory

Shenzhen, Other, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06183658

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216106 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

NCT072349426 locations

Study on the Effect of 40 Hz Non-Invasive Light Therapy System

NCT052601771 location

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203123 locations